Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Intrathecal Chemotherapy As Treatment for Chimeric Antigen Receptor T Cell (CAR T) Therapy Associated Neurotoxicity

Melhem M. Solh, Asad Bashey, Lawrence Morris, Lizamarie Bachier-Rodriguez, H Kent Holland, Xu Zhang, Katelin C Jackson, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2023-186585

Published: 2023

Journal Articles

Impact of an HLA-DPB1 Non-Permissive Mismatch By the Revised T Cell Epitope (TCE)-Core Algorithm on Survival Following Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCy)

Scott R. Solomon, Michael T Aubrey, Lizamarie Bachier-Rodriguez, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Christina Roark, H. Kent Holland, Lawrence Morris, Asad Bashey

Blood (2023) 142 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2023-182499

Published: 2023

Journal Articles

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2023-186117

Published: 2023

Journal Articles

Impact of HLA-DQ Heterodimer Group (G1/G2) Mismatch on Relapse and Survival Following Haploidentical Donor Transplantation

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Lizamarie Bachier-Rodriguez, Lawrence Morris, H. Kent Holland, Christina Roark, Katelin C Jackson, Asad Bashey, Melhem M. Solh

Blood (2023) 142 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2023-182503

Published: 2023

Journal Articles

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, Lizamarie Bachier-Rodriguez, H Kent Holland, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2023-187505

Published: 2023

Journal Articles

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Melhem M. Solh, Kristen Kilby, Jimena Baron, Xu Zhang, Asad Bashey, H Kent Holland, Lizamarie Bachier-Rodriguez, Lawrence Morris, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 5939.

https://doi.org/10.1182/blood-2023-186662

Published: 2023

Journal Articles

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Lan Lei, Asad Bashey, Scott R. Solomon, Lawrence Morris, H Kent Holland, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Lizamarie Bachier Rodriguez

Blood (2023) 142 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2023-190663

Published: 2023

Journal Articles

Effect of HLA-DPB1 Mismatch on Incidence and Severity of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation

Scott R. Solomon, Melhem M. Solh, Asad Bashey, Lizamarie Bachier-Rodriguez, Xu Zhang, Lawrence Morris, H. Kent Holland

Blood (2023) 142 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2023-182495

Published: 2023

Journal Articles

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Michael T. Aubrey, Christina L. Roark, Lawrence E. Morris, Jr., H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 4861–4862.

https://doi.org/10.1182/blood-2022-158759

Published: 2022

Journal Articles

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Rebecca Farley, Eva Karam, Xu Zhang, Asad Bashey, H. Kent Holland, Lawrence E. Morris, Jr., Scott R. Solomon, Melhem Solh

Blood (2022) 140 (Supplement 1): 11694–11695.

https://doi.org/10.1182/blood-2022-167938

Published: 2022

Journal Articles

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, Melhem Solh, Lawrence E. Morris, Jr., H. Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey

Blood (2022) 140 (Supplement 1): 1188–1189.

https://doi.org/10.1182/blood-2022-158797

Published: 2022

Journal Articles

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed, Christina L Roark, Lizamarie Bachier-Rodriguez, Lawrence E. Morris, Jr., H. Kent Holland, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 7738–7739.

https://doi.org/10.1182/blood-2022-164804

Published: 2022

Journal Articles

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Jr., Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 7647–7648.

https://doi.org/10.1182/blood-2022-162788

Published: 2022

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Asad Bashey, Xu Zhang, Scott R. Solomon, Lizamarie Bachier-Rodriguez, H. Kent Holland, Lawrence E. Morris, Jr., Melhem Solh

Blood (2022) 140 (Supplement 1): 7568–7569.

https://doi.org/10.1182/blood-2022-156852

Published: 2022

Journal Articles

Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Asad Bashey, Xu Zhang, Melhem Solh, H. Kent Holland, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 11007–11008.

https://doi.org/10.1182/blood-2022-163574

Published: 2022

Journal Articles

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Melhem Solh, Scott R. Solomon, Xu Zhang, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, H. Kent Holland, Asad Bashey

Blood (2022) 140 (Supplement 1): 4745–4746.

https://doi.org/10.1182/blood-2022-164773

Published: 2022

Journal Articles

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Asad Bashey, Lawrence E. Morris, Jr., H. Kent Holland, Melhem Solh

Blood (2022) 140 (Supplement 1): 10618–10619.

https://doi.org/10.1182/blood-2022-158803

Published: 2022

Journal Articles

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Melhem Solh, Lawrence E Morris, H. Kent Holland, Katelin C Jackson, Brian M Freed, Christina L Roark, Asad Bashey

Blood (2021) 138 (Supplement 1): 420.

https://doi.org/10.1182/blood-2021-149289

Published: 2021

Journal Articles

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Katelin C Jackson, Christina L Roark, Brian M Freed, Lawrence E Morris, H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2021) 138 (Supplement 1): 418.

https://doi.org/10.1182/blood-2021-151496

Published: 2021

NARROW

Intrathecal Chemotherapy As Treatment for Chimeric Antigen Receptor T Cell (CAR T) Therapy Associated Neurotoxicity

Impact of an HLA-DPB1 Non-Permissive Mismatch By the Revised T Cell Epitope (TCE)-Core Algorithm on Survival Following Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCy)

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Impact of HLA-DQ Heterodimer Group (G1/G2) Mismatch on Relapse and Survival Following Haploidentical Donor Transplantation

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Effect of HLA-DPB1 Mismatch on Incidence and Severity of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only